AH
TRML

Andreas Halvorsen’s Tourmaline Bio TRML Stock Holding History

Andreas Halvorsen’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-328,962
Closed -$6.18M – 97
2023
Q1 		$6.18M Hold
328,962
– – 0.03% 79
2022
Q4 		$3.36M Hold
328,962
– – 0.02% 76
2022
Q3 		$8.65M Hold
328,962
– – 0.04% 85
2022
Q2 		$14.8M Hold
328,962
– – 0.07% 80
2022
Q1 		$32.4M Hold
328,962
– – 0.13% 80
2021
Q4 		$50.3M Hold
328,962
– – 0.14% 86
2021
Q3 		$44.6M Hold
328,962
– – 0.12% 84
2021
Q2 		$48.3M Buy
+328,962
New +$50.4M 0.15% 76

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Andreas Halvorsen's TRML Position: Q2 2023 in Review

Andreas Halvorsen sold out of Tourmaline Bio (TRML) in Q2 2023, closing a stake of 328,962 shares — an estimated $6.18M sold.

Andreas Halvorsen first reported a position in TRML in Q2 2021 and held it in 8 quarters. The position peaked at $50.3M in Q4 2021. 58 funds tracked by Wall St. Rank hold TRML as of Q2 2023.

  • Andreas Halvorsen reported no remaining Tourmaline Bio position as of Q2 2023 after selling out during the quarter.
  • Andreas Halvorsen sold 328,962 Tourmaline Bio shares in Q2 2023, an estimated $6.18M.
  • Andreas Halvorsen first reported a position in Tourmaline Bio in Q2 2021 and held it in 8 quarters.
  • Andreas Halvorsen's Tourmaline Bio position peaked at $50.3M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2023.

Based on Viking Global Investors's 13F filing for Q2 2023, filed 14 Aug 2023.